Hub : Traits :

Peak expiratory flow (PEF)

853 significantly associated models · 152 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	752566	2036263	5	1	1.3e-09	1.5e-11	1.6e-03	78	PUSL1
2	1	18940380	20350374	1	1	1.5e-08	7.1e-10	1.7e-03	74	PQLC2
3	1	26061266	27488299	2	1	8.8e-09	1.5e-07	2.8e-02	82	DHDDS
4	1	77464831	79041520	2	1	1.5e-07	2.8e-07	1.0e+00	100	USP33
5	1	203793652	206329620	7	3	5.1e-23	1.3e-28	1.4e-06	81	MDM4 RAB7L1 SLC26A9
6	2	42767044	44157441	1	1	1.9e-07	2.5e-12	2.2e-06	54	AC010883.5
7	2	190689771	192091293	1	1	7.2e-08	3.5e-07	7.6e-02	88	TMEM194B
8	2	241805851	243048760	1	1	4.1e-08	2.4e-06	1.3e-01	90	BOK
9	3	49030828	50448632	1	1	1.2e-08	1.4e-04	2.6e-01	91	RNF123
10	3	128788778	129284415	1	1	3.0e-08	8.6e-07	5.5e-01	98	H1FX
11	4	4774402	5270485	1	1	1.3e-09	3.2e-13	7.0e-07	54	CYTL1
12	4	17104059	18507692	2	1	9.3e-12	5.0e-11	3.0e-02	89	DCAF16
13	4	144230902	146788825	4	3	1.1e-30	3.0e-63	6.1e-24	64	GYPA HHIP-AS1 OTUD4
14	4	169769793	170436564	1	1	1.2e-07	7.5e-07	1.8e-01	93	SH3RF1
15	5	82684424	83258483	1	1	1.3e-08	4.1e-18	5.3e-11	43	HAPLN1
16	5	147063674	148712150	2	2	5.7e-12	3.2e-15	6.9e-04	82	FBXO38
17	5	156123995	157697754	1	1	8.6e-14	8.9e-13	2.4e-01	97	ADAM19
18	6	34310476	36121375	5	2	2.0e-10	7.1e-10	1.2e-01	94	C6orf106 ZNF76
19	6	108994161	110710018	8	1	2.9e-10	3.9e-09	5.9e-01	99	SMPD2
20	6	133961374	134468561	1	1	6.6e-08	3.6e-09	8.5e-07	30	TCF21
21	6	148844451	150429697	1	1	3.0e-11	6.6e-12	1.0e+00	100	TAB2
22	7	6502367	7988091	1	1	1.7e-08	1.3e-06	6.2e-01	99	C1GALT1
23	8	8092025	10985432	8	1	1.6e-11	7.0e-12	6.9e-03	84	ERI1
24	8	11103895	12966739	5	1	2.8e-08	6.0e-08	4.1e-03	72	FAM66A
25	8	130517157	131045893	1	1	6.7e-11	3.7e-09	5.6e-01	99	GSDMC
26	9	126927285	128824378	5	1	1.9e-08	2.0e-08	1.0e+00	100	RABEPK
27	9	135629944	137034272	2	2	1.1e-10	5.9e-14	9.3e-04	81	ABO CACFD1
28	10	11477584	13569805	4	2	2.4e-14	1.2e-17	4.0e-02	94	CDC123 SEC61A2
29	10	29603847	31102564	1	1	3.7e-13	1.7e-15	3.0e-04	79	KIAA1462
30	11	65594820	67856510	3	2	4.6e-17	6.5e-16	1.0e+00	100	CCDC87 RAD9A
31	11	72325482	73717074	1	1	8.9e-08	1.1e-06	1.0e-01	89	RP11-800A3.7
32	12	49780778	51189619	1	1	9.7e-09	4.2e-08	6.1e-01	99	SMARCD1
33	12	101713020	103148974	2	1	1.6e-08	9.9e-12	1.0e-04	68	C12orf48
34	13	49905672	51390447	2	1	9.8e-10	2.8e-10	1.0e+00	100	DLEU2
35	15	70697945	72771648	1	1	1.3e-16	1.2e-14	8.8e-01	100	THSD4
36	15	83167559	84434423	1	1	5.6e-08	9.8e-08	3.3e-03	70	BTBD1
37	16	13697975	14759768	1	1	1.4e-14	2.2e-14	1.0e+00	100	RP11-65J21.3
38	16	74578110	76197034	3	1	8.4e-08	1.6e-08	1.0e+00	100	TMEM170A
39	16	89431290	89953773	1	1	2.5e-07	3.7e-08	1.3e-05	38	DPEP1
40	17	27876561	29313078	1	1	3.0e-07	2.8e-06	3.0e-01	95	BLMH
41	17	36211659	37597185	2	1	5.3e-08	6.1e-08	1.0e+00	100	PCGF2
42	17	42774693	45796313	19	1	7.7e-15	2.0e-13	2.3e-01	97	MAPT
43	17	45921906	47318157	1	1	3.2e-08	4.2e-06	2.4e-01	93	HOXB2
44	17	61106371	62694738	5	1	1.2e-10	6.4e-10	6.0e-01	99	CD79B
45	17	63601146	65498820	1	1	3.0e-07	5.2e-07	7.3e-02	87	PRKCA
46	17	79237900	80685655	6	1	1.0e-11	7.9e-11	1.0e+00	100	ASPSCR1
47	19	4153400	4687075	1	1	2.1e-07	2.5e-07	1.0e+00	100	CHAF1A
48	19	48464978	49872085	1	1	8.9e-08	2.1e-07	9.8e-02	90	NTN5
49	20	32254831	34980465	21	6	1.7e-17	2.0e-19	NaN	NaN	CEP250 GDF5 MAP1LC3A UQCC1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Lung FEV1/FVC ratio	14.62	32	20	44.4	0.85	3.2e-10	AC010883.5 ADAM19 BLMH BTBD1 C1GALT1 C6orf106 CDC123 CEP250 DHDDS FBXO38 GDF5 GYPA HAPLN1 HHIP-AS1 HOXB2 MAP1LC3A MAPT NTN5 OTUD4 PCGF2 PQLC2 RAB7L1 RNF123 RP11-800A3.7 SEC61A2 SH3RF1 SLC26A9 SMPD2 TCF21 THSD4 TMEM170A ZNF76
Sitting height	12.84	26	22	48.9	0.89	3.2e-10	ASPSCR1 BOK C6orf106 CACFD1 CD79B CEP250 DCAF16 DHDDS DLEU2 GDF5 GSDMC GYPA H1FX HHIP-AS1 HOXB2 MAP1LC3A MAPT OTUD4 PRKCA RAB7L1 RAD9A RP11-65J21.3 SMARCD1 SMPD2 UQCC1 ZNF76
Standing height	12.42	32	26	57.8	0.85	1.7e-10	ASPSCR1 BLMH BOK C6orf106 CCDC87 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 DPEP1 ERI1 FAM66A GDF5 GSDMC H1FX HHIP-AS1 HOXB2 MAP1LC3A MAPT NTN5 OTUD4 PRKCA RAB7L1 RAD9A RP11-65J21.3 SMARCD1 SMPD2 TMEM170A UQCC1 ZNF76
Height	12.31	40	34	75.6	0.83	6.7e-12	AC010883.5 ASPSCR1 BLMH BOK BTBD1 C12orf48 C6orf106 CACFD1 CCDC87 CD79B CDC123 CEP250 CHAF1A DCAF16 DHDDS DLEU2 DPEP1 GDF5 GSDMC GYPA H1FX HHIP-AS1 HOXB2 MAP1LC3A MAPT MDM4 NTN5 OTUD4 PRKCA PUSL1 RAB7L1 RAD9A RP11-65J21.3 SEC61A2 SMARCD1 SMPD2 TAB2 TMEM170A UQCC1 ZNF76
Forced expiratory volume in 1-second (FEV1)	11.57	42	34	75.6	0.97	2.1e-26	ABO ADAM19 ASPSCR1 BOK BTBD1 C12orf48 C1GALT1 C6orf106 CACFD1 CCDC87 CD79B CDC123 CEP250 DCAF16 DHDDS DLEU2 DPEP1 ERI1 FAM66A FBXO38 GDF5 GSDMC GYPA H1FX HHIP-AS1 MAPT MDM4 OTUD4 PCGF2 PQLC2 RABEPK RAD9A RNF123 RP11-65J21.3 RP11-800A3.7 SEC61A2 SH3RF1 SMARCD1 SMPD2 THSD4 USP33 ZNF76
Forced expiratory volume in 1-second (FEV1), Best measure	11.30	39	27	60.0	0.97	5.4e-24	ABO ADAM19 ASPSCR1 BOK BTBD1 C12orf48 C1GALT1 C6orf106 CACFD1 CCDC87 CD79B CDC123 CEP250 DCAF16 DHDDS DLEU2 DPEP1 ERI1 FAM66A FBXO38 GDF5 GSDMC GYPA H1FX HHIP-AS1 MAPT MDM4 OTUD4 PCGF2 RAD9A RNF123 RP11-65J21.3 RP11-800A3.7 SEC61A2 SH3RF1 SMPD2 THSD4 USP33 ZNF76
Comparative height size at age 10	10.47	27	20	44.4	0.87	6.1e-10	AC010883.5 ASPSCR1 BOK C12orf48 C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 DPEP1 GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A MAPT NTN5 OTUD4 PRKCA RAB7L1 RAD9A SMPD2 TMEM170A UQCC1 ZNF76
Trunk predicted mass	9.98	24	20	44.4	0.89	1.1e-09	ABO BOK C12orf48 C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 PRKCA RAB7L1 RAD9A RP11-65J21.3 SMPD2 UQCC1 ZNF76
Trunk fat-free mass	9.96	24	20	44.4	0.89	1.0e-09	ABO BOK C12orf48 C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 PRKCA RAB7L1 RAD9A RP11-65J21.3 SMPD2 UQCC1 ZNF76
Whole body fat-free mass	9.12	22	21	46.7	0.89	7.1e-09	BOK C12orf48 C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A RP11-65J21.3 SMPD2 UQCC1 ZNF76
Whole body water mass	9.00	22	21	46.7	0.89	6.5e-09	BOK C12orf48 C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A RP11-65J21.3 SMPD2 UQCC1 ZNF76
Forced vital capacity (FVC), Best measure	8.67	29	24	53.3	0.91	2.0e-12	ASPSCR1 BLMH BOK C12orf48 C6orf106 CACFD1 CCDC87 CD79B CDC123 CEP250 DCAF16 DHDDS DLEU2 DPEP1 GDF5 GSDMC GYPA H1FX HHIP-AS1 MAPT MDM4 OTUD4 PRKCA RAD9A RNF123 RP11-65J21.3 SMPD2 UQCC1 ZNF76
Forced vital capacity (FVC)	8.64	33	23	51.1	0.91	5.5e-14	ASPSCR1 BLMH BOK C12orf48 C6orf106 CACFD1 CCDC87 CD79B CDC123 CEP250 DCAF16 DHDDS DLEU2 DPEP1 GDF5 GSDMC GYPA H1FX HHIP-AS1 MAPT MDM4 OTUD4 PRKCA RABEPK RAD9A RNF123 RP11-65J21.3 SEC61A2 SMARCD1 SMPD2 UQCC1 USP33 ZNF76
Arm fat-free mass (right)	8.60	24	21	46.7	0.89	8.3e-10	ABO BOK C12orf48 C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A NTN5 OTUD4 RAB7L1 RAD9A RP11-65J21.3 SMPD2 UQCC1 ZNF76
Arm predicted mass (right)	8.59	23	21	46.7	0.89	2.5e-09	ABO BOK C12orf48 C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A RP11-65J21.3 SMPD2 UQCC1 ZNF76
Basal metabolic rate	8.15	22	19	42.2	0.84	2.1e-07	BOK C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 ERI1 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A RP11-65J21.3 SMPD2 UQCC1 ZNF76
Arm predicted mass (left)	8.09	22	21	46.7	0.89	4.6e-09	ABO BOK C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A RP11-65J21.3 SMPD2 UQCC1 ZNF76
Arm fat-free mass (left)	8.08	21	20	44.4	0.89	9.9e-09	BOK C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A RP11-65J21.3 SMPD2 UQCC1 ZNF76
Leg fat-free mass (right)	7.67	20	17	37.8	0.83	2.2e-06	BOK C6orf106 CD79B CEP250 CHAF1A DCAF16 DLEU2 ERI1 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A SMPD2 UQCC1 ZNF76
Leg predicted mass (right)	7.67	20	17	37.8	0.83	2.2e-06	BOK C6orf106 CD79B CEP250 CHAF1A DCAF16 DLEU2 ERI1 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A SMPD2 UQCC1 ZNF76
Forced expiratory volume in 1-second (FEV1), predicted	7.60	15	12	26.7	0.94	1.1e-08	BOK C6orf106 CD79B CEP250 DCAF16 DLEU2 GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAD9A UQCC1 ZNF76
Leg fat-free mass (left)	7.47	21	17	37.8	0.83	9.3e-07	BOK C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 ERI1 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A SMPD2 UQCC1 ZNF76
Leg predicted mass (left)	7.45	21	17	37.8	0.83	9.5e-07	BOK C6orf106 CD79B CEP250 CHAF1A DCAF16 DHDDS DLEU2 ERI1 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A SMPD2 UQCC1 ZNF76
Hand grip strength (right)	6.94	16	11	24.4	0.90	3.7e-07	C6orf106 CD79B CEP250 DCAF16 DPEP1 GDF5 H1FX HOXB2 MAP1LC3A MAPT PCGF2 RAB7L1 RABEPK RAD9A UQCC1 ZNF76
Hand grip strength (left)	6.06	18	11	24.4	0.90	8.2e-08	C12orf48 C6orf106 CCDC87 CD79B CEP250 DCAF16 DPEP1 GDF5 H1FX HOXB2 MAP1LC3A MAPT PCGF2 RAB7L1 RABEPK RAD9A UQCC1 ZNF76
Forced expiratory volume in 1-second (FEV1), predicted percentage	5.97	19	9	20.0	0.88	3.1e-07	ADAM19 ASPSCR1 BOK C1GALT1 CD79B CDC123 DHDDS ERI1 FAM66A FBXO38 HHIP-AS1 MAPT PCGF2 RNF123 SMPD2 THSD4 TMEM170A UQCC1 ZNF76
Lung FVC	5.80	32	19	42.2	0.31	6.7e-02	ABO ASPSCR1 BOK BTBD1 C12orf48 C1GALT1 CACFD1 CCDC87 CD79B CDC123 CEP250 DCAF16 DHDDS DPEP1 FBXO38 GDF5 GSDMC HOXB2 MAP1LC3A MAPT MDM4 RAD9A RNF123 SEC61A2 SH3RF1 SMPD2 TCF21 THSD4 TMEM194B UQCC1 USP33 ZNF76
Hair Pigment	5.04	10	7	15.6	-0.61	3.4e-02	AC010883.5 ASPSCR1 BTBD1 CCDC87 CEP250 DPEP1 GDF5 MAP1LC3A UQCC1 ZNF76
Weight	4.69	18	14	31.1	0.82	1.1e-05	BOK C6orf106 CD79B CEP250 DCAF16 DLEU2 ERI1 FAM66A GDF5 GSDMC H1FX HHIP-AS1 MAP1LC3A OTUD4 RAB7L1 RAD9A SMPD2 UQCC1
Tanning	4.44	5	5	11.1	0.93	2.5e-03	CEP250 DPEP1 GDF5 MAP1LC3A UQCC1
Blood clot in the leg (DVT)	3.88	2	2	4.4	0.00	1.0e+00	ABO CACFD1
Deep venous thrombosis (DVT) (self-reported)	3.83	2	2	4.4	0.00	1.0e+00	ABO CACFD1
Hip circumference	3.34	14	8	17.8	0.79	3.0e-04	BOK C6orf106 CEP250 DLEU2 ERI1 FAM66A GDF5 H1FX HHIP-AS1 MAP1LC3A OTUD4 RAD9A SMPD2 UQCC1
Knee pain experienced in last month	3.33	3	3	6.7	-1.00	3.5e-03	CEP250 GDF5 UQCC1
Neuroticism score	3.17	5	3	6.7	-0.09	8.7e-01	AC010883.5 ERI1 FAM66A FBXO38 MAPT
Relative age of first facial hair	3.04	4	3	6.7	-0.08	9.2e-01	C6orf106 DPEP1 MAPT RP11-65J21.3
Impedance of leg (left)	2.82	19	7	15.6	-0.14	5.5e-01	AC010883.5 CCDC87 CD79B CEP250 CHAF1A DPEP1 ERI1 FAM66A GDF5 H1FX HOXB2 MAP1LC3A MAPT OTUD4 RAB7L1 RAD9A SMARCD1 SMPD2 UQCC1
Systolic blood pressure, automated reading	2.79	9	6	13.3	-0.32	3.7e-01	DCAF16 ERI1 FAM66A FBXO38 KIAA1462 MAPT SMARCD1 TMEM170A TMEM194B
Impedance of leg (right)	2.75	16	9	20.0	-0.19	4.7e-01	AC010883.5 CD79B CEP250 CHAF1A ERI1 FAM66A GDF5 GSDMC H1FX MAPT OTUD4 RAB7L1 RAD9A SMARCD1 SMPD2 UQCC1
Prostate Cancer	2.73	2	1	2.2	0.00	1.0e+00	CD79B MDM4
Relative age voice broke	2.65	5	2	4.4	-0.60	2.8e-01	DPEP1 GDF5 MAPT RP11-65J21.3 UQCC1
LDL Cholesterol	2.64	3	2	4.4	0.00	1.0e+00	ABO CACFD1 NTN5
Worrier / anxious feelings	2.62	4	3	6.7	0.17	8.3e-01	C1GALT1 ERI1 FAM66A MAPT
Nervous feelings	2.61	4	3	6.7	-0.17	7.8e-01	ERI1 FAM66A FBXO38 MAPT
Hair/balding pattern: Pattern 4	2.59	3	1	2.2	0.84	1.6e-01	AC010883.5 MAP1LC3A MAPT
Sensitivity / hurt feelings	2.58	2	1	2.2	0.00	1.0e+00	FAM66A MAPT
Overall health rating	2.48	6	2	4.4	-0.99	1.8e-04	CCDC87 DCAF16 ERI1 GYPA HOXB2 RABEPK
Diastolic blood pressure, automated reading	2.48	11	6	13.3	-0.40	2.2e-01	ABO C1GALT1 DCAF16 ERI1 FAM66A HOXB2 RP11-800A3.7 SMARCD1 THSD4 TMEM194B ZNF76
High blood pressure (mother)	2.47	1	0	0.0	0.00	1.0e+00	TMEM170A
Birth weight of first child	2.45	5	2	4.4	0.99	6.7e-04	ASPSCR1 DCAF16 OTUD4 TMEM170A ZNF76
Systolic Blood Pressure	2.44	14	9	20.0	0.12	6.6e-01	C1GALT1 CDC123 CEP250 DCAF16 FBXO38 GDF5 MAPT NTN5 RP11-800A3.7 SMARCD1 TCF21 TMEM170A TMEM194B UQCC1
Mood swings	2.42	2	1	2.2	0.00	1.0e+00	FAM66A MAPT
Medication: Blood pressure	2.39	5	3	6.7	-0.14	8.2e-01	C1GALT1 DPEP1 ERI1 FAM66A MAPT
Birth weight	2.38	3	1	2.2	0.00	1.0e+00	DCAF16 GDF5 ZNF76
Waist Hip Ratio (WHR)	2.36	15	8	17.8	-0.70	3.5e-03	AC010883.5 ASPSCR1 C12orf48 CD79B CEP250 DLEU2 GDF5 H1FX HHIP-AS1 MAPT NTN5 OTUD4 RABEPK RAD9A UQCC1
Heel bone mineral density (BMD) T-score, automated (right)	2.35	5	3	6.7	-0.71	1.8e-01	DLEU2 ERI1 FAM66A HHIP-AS1 MAPT
Impedance of whole body	2.34	15	9	20.0	-0.14	6.1e-01	AC010883.5 CD79B CEP250 CHAF1A ERI1 FAM66A GDF5 MAP1LC3A MAPT OTUD4 RAB7L1 RAD9A SMARCD1 SMPD2 UQCC1
Hair/balding pattern: Pattern 3	2.33	2	1	2.2	0.00	1.0e+00	MAP1LC3A MAPT
Hypertension (Self-reported)	2.33	9	4	8.9	-0.46	2.1e-01	ABO C1GALT1 DCAF16 DPEP1 ERI1 FAM66A SMARCD1 TCF21 TMEM170A
Irritability	2.33	4	3	6.7	0.49	5.1e-01	AC010883.5 ERI1 FAM66A MAPT
High blood pressure	2.31	9	4	8.9	-0.22	5.7e-01	ABO C1GALT1 DCAF16 ERI1 FAM66A MAPT SMARCD1 TCF21 TMEM170A
High cholesterol (Self-reported)	2.31	2	1	2.2	0.00	1.0e+00	DCAF16 NTN5
Heel T-Score	2.29	18	13	28.9	-0.03	9.2e-01	ABO AC010883.5 ASPSCR1 BLMH C12orf48 CACFD1 DCAF16 DLEU2 DPEP1 GSDMC H1FX HHIP-AS1 MAP1LC3A MAPT PCGF2 PUSL1 THSD4 ZNF76
Wheeze or whistling in the chest in last year	2.29	2	0	0.0	0.00	1.0e+00	ADAM19 TAB2
Heel bone mineral density (BMD) T-score, automated (left)	2.28	5	3	6.7	-0.67	2.1e-01	DLEU2 ERI1 FAM66A HHIP-AS1 MAPT
Medication: Bendroflumethiazide	2.23	4	0	0.0	-0.59	4.1e-01	C1GALT1 ERI1 FAM66A TCF21
Vascular/heart problems diagnosed by doctor	2.23	7	5	11.1	0.59	1.6e-01	C1GALT1 DCAF16 ERI1 FAM66A SMARCD1 TCF21 TMEM170A
Lupus	2.18	3	0	0.0	0.00	1.0e+00	C6orf106 TMEM194B ZNF76
Neuroticism	2.18	3	1	2.2	0.00	1.0e+00	FBXO38 MAPT PCGF2
Diabetes diagnosed by doctor	2.18	1	1	2.2	0.00	1.0e+00	AC010883.5
Blood Red Count	2.16	13	9	20.0	-0.06	8.5e-01	ABO ASPSCR1 BLMH CACFD1 CCDC87 CD79B CHAF1A HOXB2 KIAA1462 MAPT RAD9A SMPD2 TMEM194B
Impedance of arm (right)	2.15	10	6	13.3	-0.08	8.2e-01	ABO CD79B CEP250 CHAF1A ERI1 FAM66A GDF5 MAPT RAB7L1 SMARCD1
Neuroticism (2016)	2.13	3	2	4.4	0.00	1.0e+00	ERI1 FAM66A MAPT
Neuroticism (Nagel 2018)	2.12	2	1	2.2	0.00	1.0e+00	AC010883.5 MAPT
Medication: Cholesterol lowering	2.12	1	0	0.0	0.00	1.0e+00	NTN5
Trunk fat mass	2.09	12	6	13.3	0.89	5.2e-05	BOK C6orf106 CEP250 ERI1 GDF5 H1FX MAP1LC3A MAPT OTUD4 RAD9A SMPD2 UQCC1
Medication: Simvastatin	2.09	1	0	0.0	0.00	1.0e+00	NTN5
Type 2 Diabetes (T2D) (2018)	2.05	2	2	4.4	0.00	1.0e+00	AC010883.5 C1GALT1
Asthma	2.05	2	2	4.4	0.00	1.0e+00	ADAM19 ZNF76
Coronary Artery Disease (CAD)	2.04	1	0	0.0	0.00	1.0e+00	TCF21
Fed-up feelings	2.03	2	1	2.2	0.00	1.0e+00	FAM66A MAPT
Diabetes (self-reported)	2.03	2	0	0.0	0.00	1.0e+00	AC010883.5 C1GALT1
Impedance of arm (left)	2.03	9	4	8.9	0.13	7.4e-01	ABO CD79B CEP250 CHAF1A ERI1 FAM66A MAPT RAB7L1 RAD9A
Multivitamins +/- minerals	2.01	1	0	0.0	0.00	1.0e+00	RAB7L1
Illnesses of mother	2.00	2	0	0.0	0.00	1.0e+00	DCAF16 PQLC2
Worry too long after embarrassment	2.00	3	0	0.0	0.00	1.0e+00	ERI1 FAM66A MAPT
Asthma (self-reported)	1.99	2	2	4.4	0.00	1.0e+00	ADAM19 ZNF76
Depressed Affect (Nagel 2018)	1.96	1	1	2.2	0.00	1.0e+00	MAPT
Past tobacco smoking	1.96	2	0	0.0	0.00	1.0e+00	MAP1LC3A RABEPK
Cardiovascular Disease	1.94	8	5	11.1	-0.45	2.6e-01	C1GALT1 DCAF16 DPEP1 NTN5 SMARCD1 TCF21 TMEM170A ZNF76
Respiratory disease	1.92	2	2	4.4	0.00	1.0e+00	ADAM19 ZNF76
Fluid intelligence score	1.91	3	0	0.0	0.00	1.0e+00	DCAF16 MAPT RNF123
Headache pain in last month	1.91	2	2	4.4	0.00	1.0e+00	MAPT TMEM170A
Illnesses of father: Heart disease	1.90	2	0	0.0	0.00	1.0e+00	ABO TCF21
Number of self-reported non-cancer illnesses	1.90	1	0	0.0	0.00	1.0e+00	CCDC87
Average weekly beer plus cider intake	1.90	1	0	0.0	0.00	1.0e+00	RNF123
Medication: Metformin	1.85	1	1	2.2	0.00	1.0e+00	AC010883.5
Qualifications: A levels/AS levels or equivalent	1.84	5	0	0.0	0.99	1.6e-03	DCAF16 GDF5 MAPT RNF123 UQCC1
Comparative body size at age 10	1.84	4	3	6.7	-0.57	4.3e-01	ERI1 FAM66A RAB7L1 SMARCD1
Number of treatments/medications taken	1.83	3	0	0.0	0.00	1.0e+00	C1GALT1 CCDC87 DCAF16
Chronic bronchitis/emphysema (father)	1.83	1	0	0.0	0.00	1.0e+00	HHIP-AS1
Father's age at death	1.83	1	0	0.0	0.00	1.0e+00	ERI1
Angina (self-reported)	1.83	1	1	2.2	0.00	1.0e+00	TCF21
Guilty feelings	1.83	3	0	0.0	0.00	1.0e+00	FAM66A MAPT RNF123
Medication: Paracetamol	1.82	1	1	2.2	0.00	1.0e+00	MAPT
Medication: Blood pressure	1.82	2	0	0.0	0.00	1.0e+00	ERI1 TCF21
Qualifications: College or University degree	1.81	4	2	4.4	0.98	2.3e-02	GDF5 MAP1LC3A MAPT RNF123
Medication for cholesterol	1.80	1	0	0.0	0.00	1.0e+00	MAPT
Worry (Nagel 2018)	1.78	2	1	2.2	0.00	1.0e+00	FBXO38 MAPT
Tense / 'highly strung'	1.78	4	1	2.2	0.01	9.9e-01	ERI1 FAM66A MAPT RAB7L1
Medication: Paracetamol	1.78	1	1	2.2	0.00	1.0e+00	MAPT
Hypothyroidism/myxoedema (self-reported)	1.77	4	2	4.4	0.40	6.0e-01	ERI1 FAM66A PUSL1 TMEM194B
Supplements: Fish oil (including cod liver oil)	1.77	1	0	0.0	0.00	1.0e+00	CCDC87
Angina	1.76	1	1	2.2	0.00	1.0e+00	TCF21
Mouth/teeth dental problems	1.75	1	0	0.0	0.00	1.0e+00	MAPT
Smoking status: Current	1.75	3	1	2.2	0.00	1.0e+00	C12orf48 FAM66A RABEPK
Miserableness	1.75	3	2	4.4	0.00	1.0e+00	ERI1 FAM66A MAPT
Qualifications: None of the above	1.74	1	0	0.0	0.00	1.0e+00	RNF123
Mouth/teeth dental problems: Dentures	1.73	2	0	0.0	0.00	1.0e+00	ERI1 NTN5
Bipolar Disorder or Schizophrenia	1.72	2	0	0.0	0.00	1.0e+00	BLMH DPEP1
Current tobacco smoking	1.72	3	1	2.2	0.00	1.0e+00	C12orf48 FAM66A RABEPK
Whole body fat mass	1.71	9	4	8.9	0.82	6.3e-03	C6orf106 CEP250 ERI1 GDF5 H1FX MAP1LC3A OTUD4 RAD9A UQCC1
Pulse rate, automated reading	1.71	3	3	6.7	0.00	1.0e+00	PCGF2 TCF21 TMEM194B
Heart attack/myocardial infarction (self-reported)	1.71	1	0	0.0	0.00	1.0e+00	TCF21
Allergy	1.70	1	1	2.2	0.00	1.0e+00	ABO
Leg fat percentage (right)	1.70	7	5	11.1	-0.72	6.6e-02	BLMH CD79B CEP250 DCAF16 ERI1 GDF5 UQCC1
Noisy workplace	1.68	2	0	0.0	0.00	1.0e+00	KIAA1462 MAPT
Verbal and Numeric Reasoning (VNR)	1.67	3	3	6.7	0.00	1.0e+00	DCAF16 MAPT RNF123
Medication: Amlodipine	1.67	1	0	0.0	0.00	1.0e+00	TCF21
Chest pain or discomfort	1.67	1	0	0.0	0.00	1.0e+00	C1GALT1
Heart attack	1.66	1	0	0.0	0.00	1.0e+00	TCF21
Supplements: Glucosamine	1.64	1	0	0.0	0.00	1.0e+00	FBXO38
Medication: Levothyroxine sodium	1.64	2	0	0.0	0.00	1.0e+00	ERI1 PUSL1
Hearing difficulty/problems with background noise	1.63	2	1	2.2	0.00	1.0e+00	MAPT RAB7L1
Leg fat percentage (left)	1.63	8	3	6.7	-0.73	3.9e-02	BLMH CD79B CEP250 DCAF16 ERI1 GDF5 UQCC1 ZNF76
Age when periods started (menarche)	1.62	3	1	2.2	0.00	1.0e+00	MAPT RP11-65J21.3 SMPD2
Ovarian Cancer	1.61	2	1	2.2	0.00	1.0e+00	HOXB2 MAPT
Medication for cholesterol, blood pressure or diabetes	1.61	1	0	0.0	0.00	1.0e+00	TCF21
Pain experienced in last month	1.59	2	1	2.2	0.00	1.0e+00	MAPT RABEPK
Schizophrenia (2014)	1.58	3	0	0.0	0.00	1.0e+00	DPEP1 ERI1 SH3RF1
Intelligence (Savage-Jansen 2018)	1.56	5	3	6.7	0.99	6.7e-04	BLMH DCAF16 DLEU2 MAPT RNF123
Smoking Status	1.56	2	1	2.2	0.00	1.0e+00	MAP1LC3A RABEPK
Medication for pain relief, constipation, heartburn	1.56	1	1	2.2	0.00	1.0e+00	MAPT
Suffer from 'nerves'	1.55	2	0	0.0	0.00	1.0e+00	FAM66A MAPT
Frequency of depressed mood in last 2 weeks	1.54	1	0	0.0	0.00	1.0e+00	MAPT
Handedness (chirality/laterality): Left-handed	1.54	1	1	2.2	0.00	1.0e+00	MAPT
Schizophrenia (2018)	1.53	1	0	0.0	0.00	1.0e+00	SH3RF1
Diabetes (father)	1.53	1	1	2.2	0.00	1.0e+00	AC010883.5
Arm fat mass (right)	1.53	7	3	6.7	0.22	6.4e-01	CCDC87 ERI1 FAM66A GDF5 MAP1LC3A OTUD4 UQCC1
Arm fat mass (left)	1.53	8	3	6.7	0.30	4.6e-01	CCDC87 ERI1 FAM66A GDF5 MAP1LC3A OTUD4 RAD9A UQCC1
Health satisfaction	1.52	2	0	0.0	0.00	1.0e+00	CCDC87 HOXB2
Pulse rate	1.51	1	1	2.2	0.00	1.0e+00	TCF21
Irritable Bowel Disease (IBD)	1.49	3	1	2.2	0.00	1.0e+00	ABO AC010883.5 PUSL1
Depression (Nagel 2018)	1.48	1	0	0.0	0.00	1.0e+00	MAPT
Ulcerative Colitis (UC)	1.48	2	0	0.0	0.00	1.0e+00	PUSL1 RNF123
Chronic bronchitis/emphysema (mother)	1.47	1	0	0.0	0.00	1.0e+00	HHIP-AS1
Arm fat percentage (right)	1.46	9	4	8.9	-0.84	4.6e-03	ABO BLMH CCDC87 CD79B DCAF16 ERI1 FAM66A RNF123 ZNF76
Frequency of tiredness / lethargy in last 2 weeks	1.45	1	0	0.0	0.00	1.0e+00	CCDC87
Ever smoked	1.45	1	0	0.0	0.00	1.0e+00	RABEPK
Age at first live birth	1.44	1	0	0.0	0.00	1.0e+00	DCAF16
Arm fat percentage (left)	1.44	9	3	6.7	-0.83	5.2e-03	ABO BLMH CCDC87 CD79B DCAF16 ERI1 FAM66A RNF123 ZNF76
Blood Platelet Count	1.41	15	11	24.4	-0.52	4.9e-02	AC010883.5 BLMH CACFD1 CEP250 DCAF16 GYPA HOXB2 KIAA1462 NTN5 OTUD4 PRKCA RP11-800A3.7 SMARCD1 SMPD2 TMEM170A
Mouth/teeth dental problems: Mouth ulcers	1.41	1	1	2.2	0.00	1.0e+00	MAPT
Frequency of tenseness / restlessness in last 2 weeks	1.40	1	1	2.2	0.00	1.0e+00	MAPT
Hair/balding pattern: Pattern 2	1.40	1	0	0.0	0.00	1.0e+00	MAPT
Crohns Disease (2017)	1.38	3	1	2.2	0.00	1.0e+00	ABO AC010883.5 NTN5
Loneliness, isolation	1.37	1	0	0.0	0.00	1.0e+00	MAPT
Alcohol intake frequency.	1.34	1	1	2.2	0.00	1.0e+00	MAPT
Number of live births	1.33	1	0	0.0	0.00	1.0e+00	MAPT
Triglycerides	1.29	1	0	0.0	0.00	1.0e+00	FAM66A
Hypothyroidism (self reported)	1.29	4	0	0.0	0.04	9.6e-01	NTN5 PQLC2 PUSL1 TMEM194B
Waist circumference	1.29	3	2	4.4	0.00	1.0e+00	HOXB2 OTUD4 RAD9A
Body mass index (BMI)	1.28	6	2	4.4	-0.70	1.2e-01	CCDC87 DCAF16 ERI1 FAM66A HOXB2 OTUD4
Blood White Count	1.26	9	7	15.6	-0.12	7.4e-01	ABO BLMH CACFD1 DCAF16 FBXO38 MAP1LC3A MAPT SMPD2 ZNF76
Number of incorrect matches in round	1.26	1	0	0.0	0.00	1.0e+00	BLMH
Leg fat mass (left)	1.26	4	2	4.4	-0.21	7.9e-01	ERI1 FAM66A OTUD4 RAD9A
Allergy or Eczema	1.24	3	0	0.0	0.00	1.0e+00	AC010883.5 MAP1LC3A TMEM170A
Trunk fat percentage	1.24	5	2	4.4	0.32	6.0e-01	ABO CD79B MAPT OTUD4 RAD9A
Leg fat mass (right)	1.24	5	2	4.4	-0.20	7.5e-01	BLMH ERI1 FAM66A OTUD4 RAD9A
Hayfever, allergic rhinitis or eczema	1.23	2	0	0.0	0.00	1.0e+00	AC010883.5 TMEM170A
Body fat percentage	1.23	6	1	2.2	-0.15	7.8e-01	BLMH CCDC87 CD79B DCAF16 ERI1 ZNF76
Average weekly champagne plus white wine intake	1.23	1	0	0.0	0.00	1.0e+00	MAPT
Mean time to correctly identify matches	1.22	1	1	2.2	0.00	1.0e+00	RAB7L1
Hearing difficulty/problems: Yes	1.21	1	0	0.0	0.00	1.0e+00	MAPT
Friendships satisfaction	1.21	1	0	0.0	0.00	1.0e+00	RP11-65J21.3
Chronotype (morning person)	1.17	1	0	0.0	0.00	1.0e+00	SMARCD1
Seen doctor (GP) for nerves, anxiety, tension or depression	1.16	1	0	0.0	0.00	1.0e+00	CCDC87
Ever unenthusiastic/disinterested for a whole week	1.12	1	0	0.0	0.00	1.0e+00	MAPT
Blood Eosinophil Count	1.09	10	4	8.9	0.00	9.9e-01	ABO AC010883.5 CACFD1 DLEU2 FBXO38 MAPT MDM4 PCGF2 SMPD2 ZNF76
Medication: Ibuprofen (e.g. Nurofen)	1.09	1	0	0.0	0.00	1.0e+00	MAPT
Reaction Time	1.08	1	0	0.0	0.00	1.0e+00	RAB7L1
Breast Cancer	0.90	1	1	2.2	0.00	1.0e+00	MAPT
BMI	0.83	6	1	2.2	-0.40	4.4e-01	BLMH DCAF16 GSDMC HOXB2 OTUD4 RNF123

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Uterus	6	1.06	2.9
GTEx	Ovary	11	1.21	2.8
GTEx	Brain Hypothalamus	5	0.85	2.7
GTEx	Small Intestine Terminal Ileum	5	1.08	2.7
GTEx	Vagina	6	0.94	2.7
GTEx	Artery Coronary	12	1.01	2.6
GTEx	Brain Frontal Cortex BA9	6	0.65	2.6
GTEx	Breast Mammary Tissue (Male)	11	0.92	2.6
GTEx	Cells EBV-transformed lymphocytes	10	0.70	2.6
GTEx	Colon Sigmoid	8	0.55	2.6
GTEx	Esophagus Gastroesophageal Junction	11	0.76	2.6
GTEx	Heart Atrial Appendage	13	0.82	2.6
GTEx	Heart Left Ventricle	10	0.65	2.6
GTEx	Testis	23	0.73	2.6
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	7	1.38	2.6
GTEx	Adipose Visceral Omentum	12	0.59	2.5
GTEx	Brain Cortex	8	0.77	2.5
GTEx	Brain Nucleus accumbens basal ganglia	8	0.92	2.5
GTEx	Breast Mammary Tissue	14	0.71	2.5
GTEx	Esophagus Mucosa	20	0.60	2.5
GTEx	Lung	16	0.56	2.5
GTEx	Muscle Skeletal	17	0.59	2.5
GTEx	Pancreas	13	0.80	2.5
GTEx	Skin Not Sun Exposed Suprapubic	16	0.65	2.5
GTEx	Skin Sun Exposed Lower leg	25	0.69	2.5
GTEx	Spleen	9	0.64	2.5
GTEx	Stomach	11	0.76	2.5
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	14	1.06	2.5
GTEx	Adrenal Gland	8	0.55	2.4
GTEx	Artery Aorta	16	0.54	2.4
GTEx	Artery Tibial	20	0.53	2.4
GTEx	Brain Caudate basal ganglia	6	0.65	2.4
GTEx	Brain Cerebellar Hemisphere	11	0.74	2.4
GTEx	Brain Cerebellum	13	0.66	2.4
GTEx	Brain Hippocampus	4	0.76	2.4
GTEx	Breast Mammary Tissue (Female)	12	0.73	2.4
GTEx	Colon Transverse	14	0.68	2.4
GTEx	Esophagus Muscularis	19	0.59	2.4
GTEx	Liver	3	0.42	2.4
GTEx	Nerve Tibial	18	0.42	2.4
GTEx	Prostate	7	0.84	2.4
GTEx	Thyroid	22	0.55	2.4
GTEx	Whole Blood	10	0.50	2.4
The Cancer Genome Atlas	Esophageal Carcinoma	6	0.88	2.4
The Cancer Genome Atlas	Rectum Adenocarcinoma	5	0.72	2.4
The Cancer Genome Atlas	Soft Tissue Sarcoma	9	0.84	2.4
GTEx	Adipose Subcutaneous	17	0.49	2.3
GTEx	Brain Putamen basal ganglia	5	0.80	2.3
GTEx	Cells Transformed fibroblasts	19	0.45	2.3
GTEx	Pituitary	7	0.63	2.3
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	7	0.64	2.3
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	14	0.51	2.3
The Cancer Genome Atlas	Skin Cutaneous Melanoma	2	0.37	2.3
METSIM	Adipose	13	0.28	2.2
NTR	Blood	9	0.37	2.2
ROSMAP	Brain Pre-frontal Cortex	15	0.34	2.2
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	9	0.54	2.2
The Cancer Genome Atlas	Colon Adenocarcinoma	9	0.44	2.2
The Cancer Genome Atlas	Glioblastoma Multiforme	4	0.39	2.2
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	8	0.39	2.2
The Cancer Genome Atlas	Lung Adenocarcinoma	12	0.41	2.2
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	13	0.52	2.2
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	10	0.63	2.2
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	9	0.54	2.2
The Cancer Genome Atlas	Stomach Adenocarcinoma	9	0.53	2.2
The Cancer Genome Atlas	Testicular Germ Cell Tumors	6	0.47	2.2
The Cancer Genome Atlas	Thyroid Carcinoma	18	0.35	2.2
YFS	Blood	12	0.26	2.1
CommonMind	Brain Pre-frontal Cortex	16	0.30	2.1
The Cancer Genome Atlas	Breast Invasive Carcinoma	18	0.41	2.1
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	16	0.39	2.1
The Cancer Genome Atlas	Brain Lower Grade Glioma	18	0.42	2.1
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	6	0.54	2.1
The Cancer Genome Atlas	Prostate Adenocarcinoma	22	0.48	2.1